None listed
Conditions
Interventions
None listed
Sponsors
Hanyang University Seoul Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Histologic or cytological diagnosis of urinary epithelial cell carcinoma ? Patients who are scheduled to start standard chemotherapy or are currently maintaining primary or secondary chemotherapy due to locally advanced, metastatic or recurrent diseases that cannot be cured using resection or multi-faceted treatment ? 19 years of age or older ? Platinum eligible (ECOG PS 0-2 and GFR = 30ml/min) ? A patient with a written informed consent with a date and signature stating that the patient (or legal representative) participates in the study after receiving sufficient information about the study
Exclusion criteria
Exclusion criteria: ?Tissue types other than urinary epithelial cell carcinoma (registration is possible if squamous epithelial cell carcinoma or adenocarcinoma is shown in urinary epithelial cell carcinoma) ? Patients who have completed secondary chemotherapy (avelumab maintenance is considered secondary chemotherapy, and if abelumab maintenance is applied and treatment is completed, registration is not possible.) ? Previous systemic chemotherapy (However, topical treatment such as intra-bladder chemotherapy is irrelevant). In addition, pre- or post-operative chemotherapy based on previous cisplatin and recurrence at least one year later can be enrolled in this study if other conventional chemotherapy has not been performed.) ? chemotherapy other than standard treatment (e.g., patients enrolled in clinical trials; however, patients enrolled in clinical trials but assigned to the current standard treatment group can be enrolled) ? Patients starting at less than 50% capacity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival, OS | — |
Secondary
| Measure | Time frame |
|---|---|
| 2nd Progression free survival (2nd PFS);Objective response rate;Causes of discontinuation of treatment;adverse events of special interests (AESIs) | — |
Countries
Korea, Republic of
Contacts
Public ContactJiyoon Kim
Hanyang University Seoul Hospital
Outcome results
None listed